Fig. 2
From: Mutational signatures of synchronous and metachronous brain metastases from lung adenocarcinoma
CSF cfDNA molecular characterization of patients with SBM and MBM. A. Comparison of significantly different altered genes (FDR < 0.05) between the SBM cohort (left) and MBM cohort (right); B. The variant allele frequencies of frequently altered genes in both cohorts; C. The summaries of EGFR mutation locations; D. The summaries of TP53 mutation locations; E. The fraction of affected pathways and samples in the SBM cohort; F. The fraction of affected pathways and samples in the MBM cohort